Table III.

Distribution of significant^* recurrent aCGH- detected aberrations in AML (n=48)

Chromosome	Cytoband	Event	Frequency (%)
Chr1	q23.2	CN Gain	10.4
Chr3	q26.1	CN Loss	18.8
Chr3	q11.2	CN Loss	22.9
Chr4	q28.3	CN Loss	14.6
Chr5	q31.1	CN Loss	27.1
Chr6	p21.1	CN Gain	12.5
Chr6	p25.3	CN Loss	20
Chr8	q12.3	CN Gain	22.9
Chr9	q34.13-q34.3	CN Loss	10.4

aCGH: array based comparative genomic hybridization, AML: acute myeloid leukemia, CN: copy number,

^*Aberrations observed in >10% patient samples at significance level of p<0.05, <50% overlap with known copy number variants